EUPRAXIA PHARMACEUTICALS INC. - Common Shares (EPRX) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2024 to Q4 2025

Type / Class
Equity / Common Shares
Symbol
EPRX on Nasdaq
Shares outstanding
53,310,033
Price per share
$8.66
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
13,830,451
Total reported value
$104,211,571
% of total 13F portfolios
0%
Share change
+517,128
Value change
+$5,872,102
Number of holders
35
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of EUPRAXIA PHARMACEUTICALS INC. - Common Shares (EPRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Freedman Joseph S. 10% $29,215,375 5,533,215 Joseph S. Freedman 24 Sep 2025
MANCHESTER MANAGEMENT CO LLC 9.2% -15% $40,756,586 -$7,770,133 4,904,523 -16% MORGAN C. FRANK 31 Dec 2025
Beutel, Goodman & Co Ltd. 8% $23,947,504 4,058,899 Beutel, Goodman & Co Ltd. 30 Sep 2025
DISBROW ROBERT 7% $21,052,085 3,568,150 Robert Disbrow 30 Sep 2025

As of 31 Dec 2025, 35 institutional investors reported holding 13,830,451 shares of EUPRAXIA PHARMACEUTICALS INC. - Common Shares (EPRX). This represents 26% of the company’s total 53,310,033 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of EUPRAXIA PHARMACEUTICALS INC. - Common Shares (EPRX) together control 26% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Beutel, Goodman & Co Ltd. 7% 3,709,373 -8.6% 0.17% $27,926,000
Balyasny Asset Management L.P. 2.5% 1,350,000 0% 0.02% $10,192,500
Vivo Capital, LLC 2.5% 1,350,000 0% 0.66% $10,192,500
SCOTIA CAPITAL INC. 2.4% 1,286,183 +0.65% 0.04% $9,604,679
GREAT POINT PARTNERS LLC 2.3% 1,200,000 0% 2.9% $9,060,000
Point72 Asset Management, L.P. 1.3% 712,104 0.01% $5,376,437
Ikarian Capital, LLC 1.1% 610,000 0.6% $4,605,500
Squadron Capital Management LLC 0.94% 500,000 0% 1.7% $3,775,000
Ally Bridge Group (NY) LLC 0.75% 397,895 -57% 4.8% $3,004,107
Velan Capital Investment Management LP 0.66% 352,000 0% 1.5% $2,657,600
Affinity Asset Advisors, LLC 0.56% 300,000 0% 0.16% $2,265,000
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 0.52% 278,064 0% $2,090,765
BANK OF AMERICA CORP /DE/ 0.48% 253,321 +456% 0% $1,912,574
UBS Group AG 0.41% 220,024 +130% 0% $1,661,181
ROYAL BANK OF CANADA 0.37% 196,277 -54% 0% $1,482,000
SummitTX Capital, L.P. 0.33% 175,948 0.04% $1,328,407
MARSHALL WACE, LLP 0.3% 158,133 0% $1,193,905
BOOTHBAY FUND MANAGEMENT, LLC 0.29% 156,331 0.03% $1,180,299
ACADIAN ASSET MANAGEMENT LLC 0.29% 155,766 +628% 0% $1,168,000
INGALLS & SNYDER LLC 0.15% 77,400 +31% 0.02% $584,000
GOLDMAN SACHS GROUP INC 0.11% 58,058 +45% 0% $438,338
CIBC WORLD MARKET INC. 0.11% 58,050 +287% 0% $436,536
RAYMOND JAMES FINANCIAL INC 0.1% 52,972 +59% 0% $399,939
Quadrature Capital Ltd 0.08% 43,186 0% $325,625
BANK OF MONTREAL /CAN/ 0.07% 37,250 0% 0% $280,083

Institutional Holders of EUPRAXIA PHARMACEUTICALS INC. - Common Shares (EPRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 13,830,451 $104,211,571 +$5,872,102 $7.55 35
2025 Q3 12,813,323 $75,287,324 +$63,953,992 $5.90 27
2025 Q2 1,970,076 $10,889,810 -$1,049,985 $5.76 14
2025 Q1 2,167,593 $7,087,336 +$1,118,946 $3.28 11
2024 Q4 1,826,270 $5,634,759 +$50,501 $3.17 9
2024 Q3 1,798,968 $4,545,745 +$185,000 $2.63 8
2024 Q2 1,727,190 $4,433,025 +$4,433,025 $2.58 8